We report the results of a study of survival, liver and kidney functions, and growth with a median follow-up of 24 years following liver transplantation in childhood. From 1988 to 1993, 128 children underwent deceased donor liver transplantation (median age: 2.5 years). Twenty-year patient and graft survival rates were 79% and 64%, respectively. Raised serum aminotransferase and/or γ-glutamyl transferase activities were present in 42% of survivors after a single transplantation. Graft histology (35 patients) showed signs of chronic rejection in 11 and biliary obstruction in 5. Mean total fibrosis scores were 4.5/9 and 3/9 in patients with abnormal and normal serum liver tests, respectively. Glomerular filtration rate was <90 mL·min −1 in 35 survivors, including 4 in end-stage renal disease who were undergoing dialysis or had undergone renal transplantation. Median final heights were 159 cm for women and 172 cm for men; final height was below the target height in 37 patients. Twenty-year survival after childhood liver transplantation may be close to 80%, and final height is within the normal range for most patients. However, chronic kidney disease or altered liver biochemistries are present in over one third of patients, which is a matter of concern for the future.
study is therefore to assess the survival, graft and renal function, and growth in a group of children with a median follow-up of 24 years after transplantation.
| PATIENTS AND METHODS
From January 1988 to December 1993, a total of 128 consecutive children underwent a deceased donor liver transplantation (whole, n = 47; reduced-size, n = 77; split, n = 4) in the pediatric surgery unit of Bicêtre hospital, at a median age of 2.5 years (range, 0.2-17), and were followed up in the pediatric hepatology unit of this hospital. No donor organ was obtained from executed prisoners or other institutionalized individuals. Demographics, etiology of liver condition, results of pretransplant assessment, main complications, and details of immunosuppression regimens are shown in Table 1 . Initial immunosuppression was based on a combination of cyclosporine and prednisone with azathioprine given for the first 2 weeks in 119 children, and on tacrolimus and prednisone in 5 children; 4 children died before immunosuppression could be started. Initial targets for trough levels 12 hours after the last intake of cyclosporine and tacrolimus were 250-350 ng·mL −1 and 10-15 ng·mL −1 , respectively. 5 Children were followed up as outpatients once or twice a year, with each visit including height, weight, and arterial blood pressure measurements, as well as blood sampling for the assessment of serum aminotransferases and γ-glutamyl transferase activities, serum creatinine concentrations, and calcineurin inhibitor trough levels. As a rule, the trough levels of cyclosporine/tacrolimus decreased regularly with time as the growth of the child resulted in a lower dose related to weight; for example, the mean cyclosporine trough level was 64 ng·mL −1 (±39) 10 years after transplantation. Prednisone was given on an alternate-day basis as soon as liver tests were normal and stable, which was usually 3 months after transplantation. The prednisone dose was regularly decreased thereafter; as an example, the mean prednisone dose expressed in mg·kg −1 per day was 0.075, 10 years after transplanta- Data concerning the survival of patients and grafts as well as growth, renal and graft function, and complications were collected in the medical records of the children; data concerning patients at an adult age were retrieved either from the medical records of the patients when they were followed up in the Paris area or were based on the information sent by colleagues from other parts of the country or abroad. Data concerning patient and graft survival were available for all 128 children, up to at least 20 years after transplantation for Reduced-size (n) 77
Operative deaths (n) 2
Hemofiltration for postoperative renal failure (n) 12
Reoperation for postoperative abdominal bleeding (n)
13
Primary nonfunction (n) 13
Hepatic artery thrombosis (n) 17
Portal vein thrombosis (n) 15
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Biliary complications (n) 38
Acute rejection (n) 58
Chronic rejection (n) 48
Episode(s) of acute renal failure
Primary Epstein-Barr infection (n) 75
EBV-related lymphoproliferative syndrome (n) 3
Tacrolimus-based (n) 5
Secondary switch from cyclosporine to tacrolimus (n) 46
Interval between switch and transplantation (y), median (range)
10 ( T A B L E 1 (Continued) 5 years or more after the previous graft) were performed in 9 patients; their outcomes are shown in Table 2 . Although a correlation was found between the age of the donor of the first graft and patient survival in the univariate analysis, with lower survival when the donor of first graft is older, no correlation was found in the multivariate analysis. No correlation was found between donor age and graft survival either.
| RESULTS

| Patient and graft survival
| Status of the 20-year survivors
| Graft status
Results of the serum aspartate aminotransferase, alanine aminotransferase, and γ-glutamyl transferase activity assays performed in 82 patients who survived ≥20 years after a single liver transplantation are shown in Table 3 . Raised activities were present in 17%, 29%, and 37% of patients, respectively. At least 1 of these 3 blood tests was ab- (Table 4) . No correlation was found with donor age.
The results of liver biopsy examination are shown in Table 5 . Signs of chronic rejection or signs of biliary obstruction were the main histological findings in patients with abnormal liver tests; signs of plasma cell-rich rejection were present in 6 of the 11 patients with chronic Seven patients presented with late biliary complications occurring 15 to 26 years after transplantation; the main data concerning symptoms, investigations, and outcomes are shown in Table 6 .
| Renal function (Table 7)
Sixty Table 1 ), and the presence of renal cysts on CT scan/MRI 10 years after transplantation (Table 4) . No correlation was found between cGFR at 20 years and donor age, pretransplant cGFR, or cGFR 1 year after transplant, respectively.
| Growth
At the time of transplantation, the mean height SD score was −1.3 ± 1.6 (range, −5.3 to 3.3) and the height was below −2 SD score in 35/101 children. Twenty years after transplantation, height was below −2 SD score in 14/101 patients. The mean final height was 159 cm (±7.2, SD) in females and 172 cm (±7, SD) in male patients, which is significantly lower than the parental target height (P < .0001). Thirty-seven patients did not reach their target height.
The mean final height was, however, within the normal range of the general population (SD score: −0.5 ± 1.1; range, 2.1 to −3.2).
In the multivariate analysis, the only factor found to be associated with a final height not reaching the target height was a low glomerular filtration rate calculated by the Cockroft-Gault formula 20 years after transplantation ( Normal value (n) 68
>ULN-≤ 2×ULN (n) 11
>2×ULN (n) 3
Serum alanine aminotransferase Activity U/L, median (range) 27 (7-274)
Normal value (n) 58
Serum γ-glutamyl transferase Activity U/L, median (range) 34 (8-3040)
Normal value (n) 51
>ULN-≤ 2×ULN (n) 15 > 2×ULN (n) 16
Tests correspond to the last available set and were performed 19 to 28 y after transplantation (median 23 y). n indicates number of patients with a given value, normal or raised above the upper limit of normal; ULN, upper limit of normal.
was found between final height and the duration of steroid therapy, steroid dose 1 year after transplantation, use of methylprednisolone boluses for acute rejection, or height SD score at the time of transplantation.
| Other late complications
Other late complications (>15 years after transplantation) observed in this population of 101 20-year survivors included: severe psychiatric disorders (n = 5), gout (n = 3), polycythemia (n = 3), epilepsy (n = 2), unresolved portal hypertension (n = 2), portopulmonary hypertension (n = 1), insulin-dependent diabetes mellitus (n = 2), and lymphomas (n = 2).
At the last follow-up, a median of 24 years after transplantation (range, 20-28 years) and at a median age of 27 years (range, 23-40 years), of the 97 patients for whom information was available, 40
lived with a partner, 57 were single, 17 had 1 to 4 children, 63 were employed, 10 were still attending school, and 24 were unemployed. 
| DISCUSSION
The results of this study of the actual survival of children 20 years after liver transplantation provide encouraging elements but also causes for concern. Indeed, a close to 80% actual survival is in itself relatively satisfactory for children affected by an otherwise lethal liver disease and operated on at a median age of 2.5 years with a median weight of 12.5 kg. It is better than the actual 20-year survival reported for patients transplanted at an adult age, which ranges from 21 to 52% in 4 reports. 2, 3, 14, 15 Several obvious factors explain the higher mortality in adults, including relapse of the original disease, de novo cancer, and cardiovascular complications; in this respect, it is worth noting that the actual 20-year survival rate for adults transplanted at an age <30 years is close (75%) to that reported here.
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T A B L E 4 Results of multivariate analyses using logistic regression for renal and graft function and final height for patients surviving for 20 y or more after a liver transplantation performed at a median age of 2. 
No lesions 1
For-cause biopsies: patients with abnormal serum activity of at least 1 of the 3 tests (aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transferase) at the time of biopsy; scheduled biopsies: patients with normal activity of all 3 tests at the time of biopsy. Liver allograft fibrosis score: semiquantitative assessment of severity of portal, sinusoidal, and centrilobular fibrosis graded from 0 to 3 for each location, respectively, and total score graded from 0 to 9, according to Venturi et al 7 . n indicates number of patients with a given lesion. as well as good graft survival. The results of the Japanese study are especially impressive because of the improvement in patient survival over time and the fact that it includes over 2200 children treated in 49 centers. 17 The actual 10-year survival of patients who underwent transplantation in the period from 1995 to 2005 is reported to be 83% in 1 study from centers using various modalities of grafts 20 and 78% for living donors in another. 21 It is therefore important to assess the potential impact of these advances on the future 20-year survival of these patients.
The mean final height reached by children reported here is within the limits of normal compared to the entire French population but, for one third of patients, below the target height that would be expected from their parents' heights and secular growth changes. The inability to reach target height was linked to impaired renal function and there was no relationship detected with the use of prednisone.
There have not been many reports on the final height of children after liver transplantation. The mean overall heights reported in 23 children in 1 report and 25 in another are comparable to those reported here (159 cm for females, 172-173 cm for males 22, 23 ). While these results are relatively satisfactory, there may be some room for improvement so that target height can be reached by more children.
Steroid-free immunosuppressive regimens may contribute to better growth, but this is debated, and arguments have been made to mitigate the role of steroid therapy in growth retardation, 23 even more so when alternate-day therapy is used. 24 Efforts to mitigate renal damage in children undergoing organ transplantation might be effective, as impaired renal function has a significant effect on growth velocity 25 ; this effect was indeed found in the current report. The good combined outcome on growth and on renal function 10 years after transplantation in Korean children 21 suggests that, early on, a low-dose calcineurin inhibitor combined with mycophenolate mofetil, and later on, a very low-dose calcineurin inhibitor or the withdrawal of the calcineurin inhibitor could help to improve growth as well as renal function. 26 Indeed, the fact that 34% of 20-year survivors reported here have stage 2 to 5 chronic kidney disease is a major concern. Even though it is lower than the renal damage described in adults 20 years after liver transplantation, 14, 27, 28 it is concerning because it is not known how this will evolve in adulthood and because the results reported here are based on cGFR, which overestimates the real glomerular filtration rate and does not allow for the proper identification of patients with stage 1 chronic kidney disease. 27 Moreover, 4 of the 101 20-year survivors in our study were in endstage renal disease and required dialysis or renal transplantation.
This proportion is twice as high as the 2% rate of end-stage kidney disease reported in a very large series of children at a median interval of 7.8 years after liver transplantation. 29 Renal damage is likely multifactorial, including renal lesions linked to the original liver disease (e.g. Alagille syndrome), potential pretransplant hepatorenal syndrome, severe bleeding or the need for renal replacement therapy in the early posttransplant period, acute episodes of renal failure at a distance from transplantation, as well as the renal toxicity of calcineurin inhibitors. The careful management or prevention of these factors, in particular the early introduction of mycophenolate mofetil to lower the dose of the calcineurin inhibitor and assiduous prevention of calcineurin inhibitor overdose, will be necessary if one is to improve the renal condition for these children once they reach adulthood. 27 The condition of the liver graft 20 years after the initial transplantation is also a matter of concern: abnormalities in liver tests were present in well over one third of patients, suggesting an ongoing process of liver damage, possibly related to chronic rejection or biliary problems. Several studies have reported the progression of fibrosis on liver biopsies performed from 1 to 10 years after transplantation in childhood. [30] [31] [32] The value of the results of liver histology reported here is limited by the relatively small number of biopsies available for review and by the lack of data concerning donor-specific antibodies, but they tend to confirm ongoing damage due to chronic rejection or biliary abnormalities, including cirrhosis in 7/35 samples studied. This suggests that the need for retransplantation persists well into adulthood. One may hope that the early use of tacrolimus will reduce the rate of liver damage due to chronic rejection in the long term; living related liver transplantation has also been associated with a remarkably low rate of retransplantation, at least up to 10 years after transplantation, 16, 18 which may contribute to lowering the need for retransplantation in the future.
Biliary complications, however, are present in 25% of living related liver transplantation recipients 18 and may still be a problem in the long term.
Finally, we would like to stress that, because of the relatively small population of patients in this report, the multivariate analyses may fail to identify factors that are predictive of growth and renal or liver function.
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